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Abstract
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world
and is characterized by a heterogeneous clinical course. This variability in clinical course
has spiked the search for prognostic markers able to predict patient evolution at the moment
of diagnosis. Markers demonstrated to be of value are the mutation status of the immuno-
globulin heavy chain variable region genes (IGHV) and lipoprotein lipase (LPL) expression.
High LPLmRNA expression has been associated with short treatment free (TFS) and de-
creased overall survival (OS) in CLL. The LPL SNPs rs301 (T<C), rs328 (C<G) and
rs13702 (T<C) have been associated with various metabolic disorders, but the association
with CLL evolution is unknown. Here, in a cohort of 248 patients, we show that patients with
the LPL SNP rs13702 wild-type T/T genotype had significantly shorter OS than patients
with C/C and T/C genotypes (median time until CLL related death: 90 and 156 months re-
spectively, p=0.008). The same was observed for LPL SNP rs301 (median time until CLL re-
lated death T/T: 102 and C/C, T/C: 144 months, p=0.03). Both SNPs rs301 and rs13702
were significantly associated with each other and notably, no association was found be-
tween IGHV status and presence of the SNP genotypes, indicating that these LPL SNPs
are reliable prognostic markers that could add extra prognostic and predictive information to
classical markers and help to improve the management of CLL.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and
mainly affects elderly people [1]. Given its highly variable disease course, prognostic markers
that allow for estimating the risk of disease progression and prognosis have been identified. In-
terestingly, lipoprotein lipase (LPL) was among the most differentially expressed genes re-
ported in the initial profiling studies of Rosenwald et al. and Klein et al. [2,3]. We and others
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have shown that LPLmRNA expression is associated with short treatment free (TFS) and de-
creased overall survival (OS) in CLL [4–6]. How LPL contributes to a worse outcome in CLL
and which mechanisms regulate its expression in CLL cells, remains to be elucidated.
Although the genetic basis of CLL is largely unknown, strong evidence suggests that a genet-
ic component contributes to the etiology of this disease. Approximately 10% of patients have a
family history of CLL, suggesting an inherited predisposition [7,8]. Genome-wide association
studies (GWAS) have shown that “common variants”, single nucleotide polymorphisms
(SNPs) with a population prevalence of at least 1%, contribute to this heritable risk of CLL
[9–11]. The LPL SNPs rs301 (T<C), rs328 (C<G) and rs13702 (T<C) have been associated
with various metabolic disorders, such as insulin resistance and atherosclerosis [12,13], but the
association with CLL disease evolution is unknown. Our aim was to evaluate whether these var-
iants in the LPL gene are associated with the clinical course of CLL patients.
Materials and Methods
Ethics Statement
This study was approved by the Ghent University Hospital Ethics Committee and conducted
according to the principles expressed in the Declaration of Helsinki. Patient samples were ob-
tained after written informed consent.
Patients and Sample Collection
248 patients diagnosed with CLL were included in this study. The diagnosis and clinical stage
for all patients were confirmed. Clinical stage was determined using the Binet staging system.
Flow cytometric analysis of CD38 and zeta-chain associated protein kinase of 70 kDa (ZAP70),
IGHV sequencing and cytogenetic characteristics were determined for the majority of patients
as previously described [14,15]. OS was defined from the date of diagnosis to the death of the
patient or the date of last follow-up before death. TFS was defined as the period between diag-
nosis and first CLL-specific treatment. Treatment was started when the lymphocyte count ex-
ceeded 1011 cells/L, or when patients developed massive lymphadenopathy, anemia,
thrombocytopenia, splenomegaly or infections attributed to CLL related immune defects. In-
clusion of patients was based on the availability of biological samples. Peripheral blood mono-
nuclear cells (PBMCs) in fetal bovine serum (Hyclone, Thermofisher Scientific, Waltham, MA,
USA) with 10% DMSO (Sigma-Aldrich, Diegem, Belgium) stored in liquid nitrogen were avail-
able from 169 patients. For the remaining 79 patients white blood cells stored at -80°C in etha-
nol were available.
Selection of LPL SNPs
Three SNPs, rs301, rs328 and rs13702 located in different regions of the LPL gene were selected
in this study, based on the minor allele frequency (MAF) in Caucasians, availability of Taqman
SNP genotyping assays and reports in literature. The location of the SNPs in the LPL gene and
their MAFs in Caucasians are shown in Table 1.
Genotyping
gDNA was extracted using the wizard SV 96 genomic DNA purification system (Promega, Lei-
den, The Netherlands). In case of a low yield, pre-amplification of gDNA was performed with
the GenomiPhi V2 DNA Amplification Kit (GE Healthcare, Diegem, Belgium). 10 ng of gDNA
was used in Taqman SNP genotyping assays (Applied Biosystems, Life Technologies,
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Merelbeke, Belgium) for SNPs rs301, rs328 and rs13702 on an ABI Prism 7300 Real Time PCR
System (Applied Biosystems, Life Technologies).
RNA Isolation, cDNA Synthesis and Real-Time Quantitative PCR
Total cellular RNA was extracted with the miRNeasy mini kit (Qiagen, Hilden, Germany) ac-
cording to the supplier’s instructions. Contaminating DNA was removed through DNase treat-
ment using the DNase I, Amplification Grade, kit (Life Technologies). Determination of LPL
expression levels was performed as previously described by Van Bockstaele et al. [4]. PCR reac-
tions were performed with the LightCycler 480 Probes Master mix (Roche Diagnostics, Vil-
voorde, Belgium) as a reaction mix, in a final volume of 15 μl in 384-well plate (Roche
Diagnostics). All reactions were done in duplicate, and each PCR run included controls and a
calibration curve of 6, 2-fold dilutions of cDNA from the HL-60 cell line (ATCC). Two house-
keeping genes, ACTB (primers described by [16]) and ABL1 (primers and probe described by
[17]) were used to normalize LPL expression according to Pede et al. [14]. LPLmRNA expres-
sion level was measured in 192 patients.
To determine expression levels ofmicroRNA-410 (miRNA-410),miRNA-410 specific cDNA
was synthesized using the Taqman reverse transcription kit and specific stem-loop RT primers
(Applied Biosystems, Life Technologies). PCR reactions were performed using an assay-on-de-
mand hydrolysis probe based Taqman miRNA expression assay (Applied Biosystems, Life
Technologies). For normalization, the two most stable small RNA controls (RNU 48, RNU 24)
were used [18]. All qPCR reactions were performed in duplicate on a LightCycler 480 (Roche
Diagnostics).
LPL ELISA
To determine LPL protein levels in 44 samples, patient PBMCs were lysed using a 2× concen-
trated lysis buffer composed of 0.25% Triton X-100 (MP Biomedicals, Solon, Ohio, USA), 50
mM KCL, 100 mM TrisHCL pH 7.4, 40% glycerol [19]. The total protein concentration was de-
termined using the Bio-Rad Bradford protein assay (Bio-Rad Laboratories, Nazareth, Belgium).
100 μl cellular lysate was used in a human LPL enzyme-linked immunosorbent assay (ELISA)
(Cusabio, Wuhan, China) following manufacturer’s instructions.
Fluorometric Lipase Activity Assay
Lipase activity of LPL was assessed by using the Confluolip fluorometric lipase activity assay
(Progen, Heidelberg, Germany) according to the manufacturer’s instructions. Purified LPL
from bovine milk (Sigma-Aldrich) served as a positive control.
Table 1. Overview of examined genetic variants in the LPL gene.
Caucasian
dbSNP rs number SNP location MAF exp MAF obs
rs301 T<C Intron 6 0.25 0.24
rs328 C<G Exon 9 0.13 0.12
rs13702 T<C 3'UTR 0.29 0.30
Both expected (exp) and observed (obs) minor allele frequencies (MAF) are shown for Caucasians. All
variants are in accordance with Hardy Weinberg law. rs indicates referenced SNP id number; T<C
indicates a transition of T to C nucleotide; C<G indicates a transversion of C to G nucleotide; UTR
indicates untranslated region.
doi:10.1371/journal.pone.0121526.t001
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Statistical Analysis
All statistical analyses were performed with the GraphPad statistical software (GraphPad Soft-
ware, La Jolla, CA, USA). All statistical tests were two-sided and an effect was considered statis-
tically significant at p value< 0.05. ROC curve analysis was performed to determine the LPL
mRNA expression cut-off value that best distinguished between mutated and unmutated cases.
Median levels of different markers were compared between two groups using Mann-Whitney
non parametric tests. Associations between different clinical markers were described with Pear-
son χ2 statistics (with the Yates continuity correction for 2 × 2 tables) or by calculating a Spear-
man's rank correlation coefficient. We used the Kaplan Meier method to analyze OS and TFS.
The log-rank test was used to determine significant associations between individual markers
and OS or TFS.
Results
Characterization of the Patient Cohort
The clinical and biological characteristics of the 248 CLL patients included in this study are de-
tailed in Table 2. Median age at diagnosis is 62 years (range 34–86 years) and the male:female
ratio is 2:1. The median TFS is 40 months (range 0–240 months) while the median OS is 78
months (range 1.5–240 months). 39 CLL-related deaths were observed during the
observation period.
Three SNPs in the LPL gene listed in Table 1 were examined. LPL rs301 is located in the
non-coding region of intron 6 and results in a T<C nucleotide change. LPL rs328, involving a
C<G nucleotide change in exon 9, inserts a nonsense mutation leading to a change in amino
acid 447 from a serine to an early stop codon. The third LPL SNP, rs13702 is located in the
3’UTR of the LPL gene. This nucleotide change disrupts a miRNA recognition element (MRE)
seed site (MRESS) for the humanmiRNA-410 [20].
Of all SNPs, MAFs were calculated and genotype frequencies were determined to be in ac-
cordance with Hardy-Weinberg equilibrium (Table 1). The observed MAFs were comparable
to expected frequencies in the Caucasian population, information extracted from the HapMap
database (available: http://www.ncbi.nlm.nih.gov/). There was no difference in median age at
diagnosis nor in male:female ratio for patients with wild-type or SNP alleles for all three exam-
ined LPL SNPs.
LPL SNPs are Prognostic Markers in CLL
Chi-square tests showed significant associations between IGHVmutation status and its surrogate
markers, CD38 status (p = 0.002), ZAP70 status (p<0.0001) and LPL status (p<0.0001) (see S1
Fig.). In this patient population no correlation was found between the examined LPL SNP geno-
types and age at diagnosis, gender, Binet stage or IGHVmutation status. Furthermore no correla-
tion was observed between CD38 or ZAP70 protein expression nor between the presence or
absence of chromosomal aberrations and presence of either three SNP variants (Table 2).
Log-rank tests showed a significant association between OS and Binet stage (p = 0.002),
IGHVmutation status (p<0.0001), CD38 (p = 0.04) and ZAP70 protein expression (p = 0.006).
The presence of the adverse chromosomal aberration del17p was also significantly associated
with OS (p = 0.008). All prognostic markers were significantly associated with TFS, except
presence or absence of del13q and del11q (see Table 3). Kaplan-Meier survival curves for TFS
with regard to IGHVmutation status (1A) and LPL expression (1B) are shown in Fig. 1.
Although none of the examined SNPs correlated significantly with well-known prognostic
markers in CLL, two of them, rs301 and rs13702, were significantly associated with OS (Log-
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Table 2. Clinical and biological characteristics among LPL rs301, rs328 and rs13702 Genotypes.
rs301 TT rs301 TC/CC
Characteristic n % n % pa
No of patients 146 59.1 101 40.9
HWEc 58.0 42.0 0.322
Gender
Male 100 59.2 69 40.8 1.000
Female 46 59.0 32 41.0
Median age at diagnosis 63 62 0.651b
Age
<60 years 59 60.8 38 39.2 0.786
60 years 85 58.2 61 41.8
Binet stage
A 106 57.9 77 42.1 0.404
B/C 31 66.0 16 34.0
IGHV
Mutated 74 58.7 52 41.3 0.972
Unmutated 48 60.0 32 40.0
CD38
<7% 68 54.8 56 45.2 0.224
7% 65 63.7 37 36.3
ZAP70
<20% 75 60.5 49 39.5 1.000
20% 54 61.4 34 38.6
LPL
negative 62 63.3 36 36.7 0.821
positive 57 60.6 37 39.4
LDT
 1 year 71 61.2 45 38.8 0.662
< 1 year 55 57.3 41 42.7
Cytogenetics
normal 36 61.0 23 39.0 0.590
chromosomal aberrations 87 55.8 69 44.2
Del13q
absent 68 63.6 39 36.4 0.232
present 51 54.3 43 45.7
Del11q
absent 109 58.3 78 41.7 0.606
present 11 50.0 11 50.0
Del17p
absent 106 55.5 85 44.5 0.563
present 13 65.0 7 35.0
rs328 CC rs328 CG/GG
Characteristic n % n % Pa
No of patients 195 78.6 53 21.4
HWEc 77.9 22.2 0.123
Gender
Male 134 78.8 36 21.2 1.000
Female 61 78.2 17 21.8
(Continued)
LPL SNPs Correlate with Outcome in CLL
PLOSONE | DOI:10.1371/journal.pone.0121526 March 26, 2015 5 / 15
Table 2. (Continued)
rs301 TT rs301 TC/CC
Characteristic n % n % pa
Median age at diagnosis 62 62 0.878b
Age
<60 years 79 80.6 19 19.4 0.752
60 years 114 78.1 32 21.9
Binet stage
A 144 78.3 40 21.7 0.610
B/C 39 83.0 8 17.0
IGHV
Mutated 104 81.9 23 18.1 0.421
Unmutated 61 76.3 19 23.8
CD38
<7% 99 79.8 25 20.2 0.954
7% 81 78.6 22 21.4
ZAP70
<20% 99 79.2 26 20.8 0.867
20% 68 77.3 20 22.7
LPL
negative 83 84.7 15 15.3 0.483
positive 75 79.8 19 20.2
LDT
 1 year 92 79.3 24 20.7 1.000
< 1 year 77 79.4 20 20.6
Cytogenetics
Normal 46 78.0 13 22.0 1.000
Chromosomal aberrations 123 78.3 34 21.7
Del13q
absent 85 78.7 23 21.3 1.000
present 74 78.7 20 21.3
Del11q
absent 150 79.8 38 20.2 0.144
present 14 63.6 8 36.4
Del17p
Absent 149 77.6 43 22.4 0.316
Present 18 90.0 2 10.0
rs13702 TT rs13702 TC/CC
Characteristic n % n % pa
No of patients 123 50.0 123 50.0
HWEc 49.1 50.9 0.413
Gender
Male 87 51.5 82 48.5 0.582
Female 36 46.8 41 53.2
Median age at diagnosis 63 62 0.501b
Age
<60 years 48 49.5 49 50.5 1.000
60 years 73 50.3 72 49.7
(Continued)
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rank test; p = 0.03 and p = 0.008 respectively). Indeed, patients being either heterozygous or ho-
mozygous for these SNPs showed a better outcome in terms of OS compared to patients having
the wild-type genotype. This was not the case for rs328 (p = 0.483) and notably none of the
SNPs affected TFS significantly. Fig. 2 shows the Kaplan Meier curves for OS.
LPL SNPs and LPL expression
GWAS have reported several genetic variants in the LPL gene affecting lipid profile levels,
among them the LPL SNPs analyzed in present study. For LPL rs301 a direct effect on LPL
Table 2. (Continued)
rs301 TT rs301 TC/CC
Characteristic n % n % pa
Binet stage
A 87 47.8 95 52.2 0.202
B/C 28 59.6 19 40.4
IGHV
Mutated 61 48.8 64 51.2 0.369
Unmutated 45 56.3 35 43.8
CD38
<7% 58 47.5 64 52.5 0.551
7% 54 52.4 49 47.6
ZAP70
<20% 62 50.0 62 50.0 0.663
20% 47 54.0 40 46.0
LPL
negative 49 50.5 48 49.5 0.877
positive 49 52.7 44 47.3
LDT
 1 year 61 53.5 53 46.5 0.298
< 1 year 44 45.4 53 54.6
Cytogenetics
Normal 29 50.0 29 50.0 1.000
Chromosomal aberrations 77 49.4 79 50.6
Del13q
absent 55 51.4 52 48.6 0.968
present 49 52.7 44 47.3
Del11q
absent 96 51.6 90 48.4 0.126
present 7 31.8 15 68.2
Del17p
absent 93 48.9 97 51.1 0.920
present 9 45.0 11 55.0
a Cross-tabulations of prognostic markers versus LPL SNP genotypes. p values of Pearson χ² statistics (with the Yates continuity correction for 2x2
tables)
b p value of Mann-Whitney non parametric test comparing median age at diagnosis between LPL SNP genotypes
c HWE, Hardy-Weinberg equilibrium
doi:10.1371/journal.pone.0121526.t002
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Table 3. Survival data for different biological and clinical characteristics and LPL SNPs.
Characteristic Median OSb pa Median TFSb pa
Binet stage
A UDc 0.002 87.2 < 0.0001
B/C 137.2 29.0
IGHV
Mutated UD < 0.0001 101.0 < 0.0001
Unmutated 165.0 36.0
CD38
<7% UD 0.042 97.0 <0.0001
7% UD 40.4
ZAP70
<20% UD 0.006 97.0 < 0.0001
20% 170.0 36.0
LPL
Negative UD 0.282 89.9 0.001
Positive UD 41.6
LDT
 1 year UD 0.167 88.1 0.001
< 1 year UD 41.6
Cytogenetics
Normal UD 0.124 96.0 0.016
Chromosomal aberrations UD 61.0
Del13q
absent UD 0.168 67.0 0.748
present UD 73.0
Del11q
absent UD 0.854 73.0 0.244
present UD 36.0
Del17p
absent UD 0.008 75.7 0.016
present 133.0 26.7
LPLrs301
TT UD 0.026 72.0 0.953
TC/CC UD 93.7
LPLrs328
CC UD 0.483 75.7 0.477
CG/GG UD 67.0
LPLrs13702
TT UD 0.008 66.0 0.678
TC/CC UD 87.2
a p values of log-rank tests
b Survival curves for overall survival (OS) and treatment free survival (TFS) were estimated by the Kaplan-Meier method
c UD, undetermined, indicating that the median value was not reached
doi:10.1371/journal.pone.0121526.t003
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Fig 1. Kaplan Meier survival curves for TFS with regard to IGHVmutation status (A) and LPLmRNA
expression (B). IGHV gene mutation status was based on a 98% cut-off value (n = 207; M, mutated; U,
unmutated). Differentiation between LPL positive and negative cases was based on the optimal cut-off value
determined by ROC curve analysis (n = 192). Log-rank tests showed significantly different TFS curves for
IGHVmutation status (p<0.0001) and LPLmRNA expression (p = 0.001).
doi:10.1371/journal.pone.0121526.g001
LPL SNPs Correlate with Outcome in CLL
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expression or activity was not reported yet. Rs328 and rs13702 however are extensively studied
gain-of-function variants, known to increase LPL activity.
Since two of these SNPs were significantly associated with outcome of CLL patients in this
cohort, we wanted to evaluate whether these SNPs affected LPL expression levels and lipase ac-
tivity. For all three variants examined we couldn’t find a significant difference in LPLmRNA
Fig 2. Kaplan-Meier curves for OS according to LPL SNP rs301 (A), rs328 (B) and rs13702 (C)
genotypes. A significant effect on OS was indicated by Log-rank tests for rs301 (n = 247; p = 0.03) and for
rs13702 (n = 246; p = 0.008), but not for rs328 (n = 248; p = 0.483).
doi:10.1371/journal.pone.0121526.g002
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expression levels between patients carrying the wild-type allele or the SNP allele (rs301;
p = 0.94, rs328; p = 0.64, rs13702; p = 0.67). LPL protein levels did not correlate with LPL
mRNA expression levels (Spearman’s rank correlation coefficient = 0.29, Fig. 3A). Comparable
to what was found on mRNA level, we couldn’t find a significant association between LPL pro-
tein levels and presence of any of the LPL SNPS (rs301; p = 0.44, rs328; p = 0.56, rs13702;
p = 0.58). Finally, we also investigated whether there is a difference in lipase activity between
samples of patients carrying one of the SNP alleles or not. As published before by others [21],
we could not, or only at a very low level, detect lipase activity in CLL cell lysates and no further
analyses were performed.
The LPL SNP rs13702 was shown to modulate lipid levels through disruption of a binding
site in the 3’UTR of the LPL gene for the humanmiRNA-410 resulting in a gain-of-function
variant [20]. To see whether thismiRNA-410 affects LPL expression in CLL cells as well, we de-
termined its expression in 25 CLL patient samples with varying LPL mRNA and protein levels.
Overall the expression levels of this miRNA in the selected CLL samples were very low and no
significant association with LPL mRNA or protein levels could be observed (Fig. 3B and 3C),
although the latter showed a trend of inverse correlation.
Discussion
In the present study we examined three SNPs in the LPL gene, rs301, rs328 and rs13702, in a
cohort of 248 CLL patients and found that rs301 and rs13702 affected OS significantly, whereas
no association with OS could be observed for rs328.
Based on these findings, we also investigated whether the LPL SNP genotypes correlated
with other well known prognostic markers in this CLL patient population. Notably, no associa-
tion with the IGHVmutation status, the gold standard in CLL prognostication, could be ob-
served. This indicates that the SNPs rs301 and rs13702, showing a significant correlation with
OS, are no surrogate markers for the IGHVmutation status, but could function as independent
prognostic markers in CLL. In line with these results none of the SNPs showed a correlation
with other prognostic markers such as ZAP70, CD38 or FISH. This independency was
highlighted by Malek as one of the reasons positively affecting the applicability of a CLL bio-
marker [22]. However, in a multivariate analysis including age at diagnosis, IGHV, ZAP70,
LPL, CD38, del11q, del17p and the three LPL SNPs, only age, ZAP70 and del17p were signifi-
cant and independent predictors of OS (age; p = 0.003, ZAP70; p = 0.009, del17p; p = 0.02). We
could not show that the LPL SNPs have additional prognostic value, which is probably due to a
lack of power in our study.
Other characteristics of a perfect CLL biomarker that are fulfilled for the SNPs we describe,
include the use of a widely available, reliable and valid measuring technique, the fact that geno-
typing can be performed in peripheral blood samples, the stability of the SNP status over time
and the fact that these SNP markers don’t require the use of arbitrary cut-off values for marker
positivity, unlike most currently available biomarkers. Moreover, in case no RNA or protein is
available, this DNA based marker can still provide prognostic information. This is in contrast
with the labor-intensive procedure required for IGHVmutation status analysis or the ZAP70
analysis which is extremely difficult to standardize.
A major shortcoming of these SNP prognostic markers is the fact that these LPL SNPs, as
far as we know now, do not represent a biological mechanism directly involved in CLL cell biol-
ogy. For LPL mRNA or protein however such a relationship with an intrinsic feature of the leu-
kemic cells was not identified either.
The LPL SNPs rs301 and 13702 affected OS significantly, but did not correlate with TFS in
this CLL patient cohort, indicating that disease progression is not affected. We speculate that
LPL SNPs Correlate with Outcome in CLL
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Fig 3. Correlation between LPL protein expression and LPLmRNA expression (A) and between
miRNA-410 expression and LPLmRNA (B) or LPL protein (C) expression.MiRNA-410mRNA (n = 25)
and LPLmRNA (n = 92) expression levels were determined by qPCR analysis, LPL protein levels were
determined by ELISA (n = 44). No correlation was found between LPL protein and mRNA levels (Spearman’s
rank correlation coefficient = 0.29) (A). No significant correlation betweenmiRNA-410 expression and LPL
mRNA (B) or protein levels (C) could be observed.
doi:10.1371/journal.pone.0121526.g003
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CLL patients carrying these SNPs are in an overall better shape and are less vulnerable to infec-
tions or respond better to therapy, explaining the observed association with better disease out-
come. These genotypes might not affect disease outcome or therapy responsiveness due to an
intrinsic effect on CLL cell biology, but could affect CLL comorbidity. Since CLL is mainly a
disease of the elderly, patients are often compromised by co-existent pathological conditions or
deterioration of their overall health. In a study investigating the effect of CLL on the quality of
life, 71.5% of 1482 patients that were included had at least one co-morbid health problem, with
hypertension and increased cholesterol being the most frequent comorbidities [23]. Both con-
ditions were demonstrated to be affected by the presence of the LPL SNPs under study [12,13].
Indeed these SNPs were found to be among the list of LPL variants positively affecting ‘healthy’
HDL cholesterol (HDL-C) and triglyceride (TG) levels, being important risk factors for these
and other pathological conditions [12,13]. The mechanism by which rs301 affects HDL-C and
TG levels is unknown yet, for rs328 and rs13702 however possible explanations for the ob-
served phenotypes were reported. The LPL SNP rs13702 was shown to modulate lipid levels
through disruption of a MRESS in the 3’UTR of the LPL gene for the humanmiRNA-410. Rich-
ardson et al. found that while in the majority of the people binding ofmiRNA-410 to the LPL
mRNA reduced synthesis of LPL, carriers of the genetic variant rs13702 showed no miRNA ac-
tivity, presumably higher LPL levels and as a consequence lower TG levels and higher HDL-C
levels [20]. Also for rs328 a mechanism has been described by which this variant contributes to
favorable lipid profiles and reduces the risk for common disease. This nucleotide polymor-
phism in exon 9 of the LPL gene, introduces a premature stop codon resulting in a truncated
protein with a higher activity giving a comparable phenotype (lower TG, higher HDL-C) as ob-
served for rs13702 carriers [24].
Despite the observed effect of rs13702 and rs328 on lipase activity reported by others, we
couldn’t find an association between presence of any of these SNPs and LPL mRNA or protein
levels, suggesting that LPL expression is controlled by other not yet defined mechanisms in
CLL cells. We also tried to compare the lipase activity between CLL samples with different ge-
notypes for the SNPs under study, but overall lipase activity was very low to undetectable,
which is in accordance with previous findings [21]. However, the biological role of LPL in CLL
remains to be elucidated, indicating that a not yet defined mechanism could be responsible for
the observed results as well.
The LPL SNPs that we evaluated in this study display important features that other current-
ly available markers often lack, making them reliable prognostic markers that could help to im-
prove the management of CLL. In this respect, it would be interesting to evaluate the clinical
utility, stability and robustness of these genetic prognostic indicators, alone or in combination
with each other and other clinical markers in large patient cohorts [25].
Supporting Information
S1 Fig. Correlation between CD38 (A), ZAP70 (B) or LPL (C) expression and IGHV status.
CD38 (n = 218) and ZAP70 (n = 167) protein expression were determined by flow cytometry,
LPLmRNA expression was determined by qPCR analysis (n = 92). IGHV gene mutation status
was based on a 98% cut-off value (n = 207). Mann-Whitney non parametric tests showed sta-
tistically significant differences between the median CD38 (p = 0.002), ZAP70 (p<0.0001) and
LPL (p<0.0001) expression levels in IGHVmutated (M) and unmutated (U) CLL cases.
(TIF)
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